Nat Med: Clinical studies of patients with non-small cell lung cancer who can undergo surgery with the new auxiliary drug Narvon anti-monodrive therapy or combined Ipi monotherapy

More than 50% of patients with surgically treatable metastasis non-small cell lung cancer (NSCLC) relapse only after surgery.
Chemotherapy during peri-surgery (new adjoytherapy or ancillary therapy) can only slightly improve the patient's 5-year total survival (OS) (approximately 5%) and may produce chemotherapy toxicity, indicating that a new treatment strategy is needed in this case.
previous studies have shown that immuno checkpoint inhibitors (ICI) targeting CTLA-4 (cytotoxic T lymphocyte antigen 4), PD-1 (programmed death subject 1) and its ligation PD-L1 can change standard treatment strategies in patients with late NSCLC.
anti-PD-1 drug nivolumab and anti-CTLA-4 drug ipilimumab can enhance anti-tumor immunity through unique non-redundant cellular mechanisms, and provide a theoretical basis for the combination of the two treatment of patients with advanced NSCLC.
the efficacy of the combined treatment and the impact on the immune micro-environment of patients with surgically available NSCLC.
Pathological and radiotherapy responses in two treatment groups in the study, the researchers reported 44 surgically performable NSCLC patients and conducted phase 2 randomized NEOSTAR clinical trials (NCT03158129) of the new complementary drug Narvon anti-monodrive therapy or navudosant anti-monotherapy with the primary pathological response (MPR) as the primary endpoint.
compared past history of complementary chemotherapy, the researchers tested the MPR rate for each treatment group.
results showed that the combined treatment group exceeded the target of reaching the main endpoint in 6 of the 21 patients expected to reach the MPR rate of 38% (8/21).
22% (5/23) in the navudosant antidr drug treatment group.
of the 37 patients in the two treatment groups who underwent surgery for survival outcomes, the MPR rates of Navudo single-drug therapy and combined therapy were 24% (5/21) and 50% (8/16), respectively.
Compared to navudosant anti-monotherapy, combined therapy showed higher pathological complete remission rates (10% to 38%), fewer tumors survived (median 50% to 9%), and a higher proportion of effect T cells, tissue resident memory T cells, and effect memory T cells.
increase in the number of gastroenteroccal genus intestinal tumors and Akkermansia spp, which are associated with dual-therapy MPR.
In summary, the results of this study show that the treatment based on the new auxiliary drug navusin anti-combination ipi monoantigen can effectively enhance the pathological response, tumor immunoinfestion and immune memory of patients, and suggest further research on its role in surgically available NSCLC patients.